Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib, randomized, placebo controlled, double blind study to determine the safety, viral suppression, pharmacokinetics and immune modulatory effects of treatment with aprepitant (Emend) in HIV infected individuals

Trial Profile

A phase Ib, randomized, placebo controlled, double blind study to determine the safety, viral suppression, pharmacokinetics and immune modulatory effects of treatment with aprepitant (Emend) in HIV infected individuals

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jun 2021 Results of pooled analysis of data from 3 phase Ib studies (NCT00428519, NCT01300988, and NCT02154360) assessing the effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naive adults living with HIV published in the Medicine
    • 18 Jul 2010 Results have been presented at the 18th International AIDS Conference.
    • 27 Apr 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top